Founders Capital Management Cut Its Abbvie (ABBV) Stake; Pimco Income Opportunity Fund (PKO) Sentiment Is 0.82

June 20, 2018 - By Hazel Jackson

AbbVie Inc. (NYSE:ABBV) Logo

Founders Capital Management Llc decreased Abbvie Inc (ABBV) stake by 24.46% reported in 2018Q1 SEC filing. Founders Capital Management Llc sold 8,258 shares as Abbvie Inc (ABBV)’s stock declined 16.83%. The Founders Capital Management Llc holds 25,502 shares with $2.33 million value, down from 33,760 last quarter. Abbvie Inc now has $148.39 billion valuation. The stock decreased 0.48% or $0.47 during the last trading session, reaching $98.01. About 5.53 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since June 20, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: ; 21/05/2018 – Gilead’s Harvoni Falls After 2-Wk Rise, Epclusa Declines: Hep-C; 13/03/2018 – ABBVIE INC – RESULTS WERE CONSISTENT WITH FIRST PHASE 3 STUDY; 09/04/2018 – STAT Plus: Pharmalittle: Novartis pays $9 billion for gene therapy company; Merck’s Keytruda scores a win; 10/04/2018 – AbbVie Remains Confident in NDA and Continues to Work With FDA to Bring Elagolix to Patients; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell; 17/04/2018 – Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia; 26/04/2018 – ABBVIE INC SAYS 2018 ADJUSTED SHR OUTLOOK REFLECTS EFFECTIVE TAX RATE APPROACHING 9 PCT IN 2018; 23/03/2018 – INNATE PHARMA SA – PARTNER MEDIMMUNE EXPANDS COLORECTAL CANCER PATIENT COHORT IN ONGOING PHASE l TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB); 31/05/2018 – Phase l/Il Study Design of Birinapant in Combination With Keytruda® to be Presented on June 4 at the ASCO Annual Meeting; 15/04/2018 – Merck: Keytruda First Anti-PD-1 Therapy to Show Recurrence-Free Survival Benefit Across Stage IIIA, IIIB, IIIC Melanoma

Pimco Income Opportunity Fund (PKO) investors sentiment decreased to 0.82 in 2018 Q1. It’s down -0.18, from 1 in 2017Q4. The ratio has dropped, as 9 active investment managers started new or increased holdings, while 11 decreased and sold stock positions in Pimco Income Opportunity Fund. The active investment managers in our database now own: 1.74 million shares, down from 1.90 million shares in 2017Q4. Also, the number of active investment managers holding Pimco Income Opportunity Fund in top ten holdings was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 6 Increased: 7 New Position: 2.

Founders Financial Securities Llc holds 0.28% of its portfolio in PIMCO Income Opportunity Fund for 33,655 shares. Horizon Kinetics Llc owns 135,341 shares or 0.1% of their US portfolio. Moreover, Cohen & Steers Inc has 0.05% invested in the company for 593,549 shares. The California-based Granite Investment Partners Llc has invested 0.02% in the stock. Sigma Planning Corp, a Michigan-based fund reported 11,050 shares.

The stock increased 0.63% or $0.17 during the last trading session, reaching $27.09. About 34,549 shares traded. PIMCO Income Opportunity Fund (PKO) has risen 4.48% since June 20, 2017 and is uptrending. It has underperformed by 8.09% the S&P500.

More news for PIMCO Income Opportunity Fund (NYSE:PKO) were recently published by:, which released: “Credit Agricole eyeing SocGen’s Polish arm Eurobank: Bloomberg” on June 19, 2018.‘s article titled: “These 15 Closed-End Funds Are Consistent Market Beaters – Part 1” and published on June 05, 2018 is yet another important article.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 earnings per share, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98 billion for 12.44 P/E if the $1.97 EPS becomes a reality. After $1.87 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

Investors sentiment decreased to 0.7 in 2018 Q1. Its down 0.10, from 0.8 in 2017Q4. It worsened, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Pekin Singer Strauss Asset Il has invested 0.67% in AbbVie Inc. (NYSE:ABBV). California State Teachers Retirement Sys stated it has 0.55% of its portfolio in AbbVie Inc. (NYSE:ABBV). Norinchukin Financial Bank The has 0.36% invested in AbbVie Inc. (NYSE:ABBV) for 228,085 shares. Alta Management Limited Liability stated it has 0.13% in AbbVie Inc. (NYSE:ABBV). Financial Bank Of Nova Scotia accumulated 0.13% or 270,898 shares. Westwood Holdg Gp Inc Inc invested 0.01% of its portfolio in AbbVie Inc. (NYSE:ABBV). Chesley Taft & Assocs Ltd Liability stated it has 95,145 shares or 0.8% of all its holdings. Caprock Gp invested in 16,479 shares or 0.33% of the stock. Palisades Hudson Asset Mgmt Lp invested in 0.25% or 4,876 shares. Hillsdale Inc has invested 0.06% of its portfolio in AbbVie Inc. (NYSE:ABBV). Badgley Phelps & Bell Inc reported 0.13% of its portfolio in AbbVie Inc. (NYSE:ABBV). Hamlin Cap Mgmt Limited Co invested 2.22% of its portfolio in AbbVie Inc. (NYSE:ABBV). Savings Bank Hapoalim Bm owns 5,500 shares for 0.14% of their portfolio. Mgmt Professionals Inc reported 699 shares. Wealthfront owns 79,606 shares for 0.08% of their portfolio.

Since February 19, 2018, it had 0 buys, and 9 sales for $25.06 million activity. 8,280 shares were sold by GONZALEZ RICHARD A, worth $976,084. Shares for $9.57M were sold by ALBAN CARLOS on Wednesday, February 28. Schumacher Laura J sold $2.95 million worth of stock. 18,129 AbbVie Inc. (NYSE:ABBV) shares with value of $2.15 million were sold by RICHMOND TIMOTHY J.. On Monday, February 19 the insider Michael Robert A. sold $119,351. SEVERINO MICHAEL had sold 2,643 shares worth $311,684 on Wednesday, February 28. 70,928 shares were sold by CHASE WILLIAM J, worth $8.31 million on Wednesday, February 28.

Among 24 analysts covering Abbvie Inc (NYSE:ABBV), 9 have Buy rating, 3 Sell and 12 Hold. Therefore 38% are positive. Abbvie Inc has $15700 highest and $6 lowest target. $99.58’s average target is 1.60% above currents $98.01 stock price. Abbvie Inc had 96 analyst reports since July 21, 2015 according to SRatingsIntel. SunTrust maintained the shares of ABBV in report on Thursday, March 22 with “Buy” rating. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by Jefferies on Friday, August 18. BMO Capital Markets maintained AbbVie Inc. (NYSE:ABBV) rating on Wednesday, June 7. BMO Capital Markets has “Hold” rating and $6600 target. The rating was maintained by UBS with “Neutral” on Friday, October 13. On Sunday, October 29 the stock rating was maintained by SunTrust with “Buy”. The rating was maintained by Jefferies on Friday, January 26 with “Buy”. The firm earned “Buy” rating on Thursday, May 25 by Jefferies. Barclays Capital maintained it with “Equal-Weight” rating and $102 target in Thursday, April 5 report. The firm has “Underperform” rating given on Wednesday, May 30 by Credit Suisse. Piper Jaffray maintained the shares of ABBV in report on Tuesday, April 10 with “Buy” rating.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News